Armata Pharmaceuticals, Inc. 8-K

Summary

CFO appointment. Armata promoted David House to CFO, effective 7/17/2026; he had served as SVP of Finance and principal financial officer since 8/2024. The company also aligned Chief Business Officer Pierre Kyme’s change-in-control definition with House’s and other senior executives’ agreements.

Key Figures

• House’s annual base salary is $0.371M, with a target annual bonus of 50% of base salary.
• The compensation committee’s current intent is to grant House annual equity awards with a grant-date fair value of ≈$0.3M beginning in FY2026; the agreement does not guarantee a specific award.
• Following a qualifying termination without Cause or resignation for Good Reason, House is eligible for 12 months of base-salary continuation, subject to a release and compliance with restrictive covenants. An involuntary termination within one month before or 12 months after a change in control accelerates time-based vesting of his outstanding equity awards.